Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Non-Current Assets data on file, last reported at $25.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 18.47% year-over-year to $25.2 million in Q1 2026; TTM through Mar 2026 was $111.0 million, a 32.67% decrease from a year earlier, with the FY2025 full-year figure at $27.3 million, down 13.28% from the prior year.
• Non-Current Assets for Q1 2026 stood at $25.2 million, down from $27.3 million in the prior quarter.
• Over the last five years, Non-Current Assets for COGT reached as high as $69.5 million in Q3 2023 and fell as low as $12.1 million in Q1 2022.
• Historically, Non-Current Assets has averaged $37.4 million across 5 years, with a median of $35.1 million in 2022.
• Across the five-year window, Non-Current Assets surged 393.68% in 2022 and sank 50.29% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $35.8 million in 2022, then grew by 19.03% to $42.7 million in 2023, then declined by 26.34% to $31.4 million in 2024, then slipped by 13.28% to $27.3 million in 2025, then dropped by 7.52% to $25.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $25.2 million in Q1 2026, $27.3 million in Q4 2025, and $28.7 million in Q3 2025.